Evaluation of IFN-gamma secretion after stimulation with C. neoformans and C. gattii antigens in individuals with frequent exposure to the fungus

Carregando...
Imagem de Miniatura
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
MASSON EDITEUR
Citação
JOURNAL DE MYCOLOGIE MEDICALE, v.32, n.2, article ID 101230, 5p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
In this study we produced antigenic extracts from prototypical strains of C. neoformans (VNI-VNIV) and C. gattii (VGI-VGIV) and tested IFN-gamma secretion by Elispot. Antigens from the eight Cryptococcus molecular types (VNI -VNIV and VGI - VGIV) were obtained after capsule reduction. IFN-gamma secretion by Elispot method were stimulated with C. neoformans and C. gattii antigens. Peripheral blood mononuclear cells of fourteen healthy control subjects, being: five ecotourists, two mycologists, three poultry keepers, and four individuals without reports of exposure to the fungus. We observed a significant increase in IFN-gamma secretion in the group of ecotourists, mycologists and bird keepers in relation to the group of individuals without reports of occupational exposures to these agents. Our results suggest the significant increase in IFN-gamma secretion may be related to the continuous exposure of these groups of individuals to the fungus, as well as to the specific antigen memory immune response developed during exposure to Cryptococcus.
Palavras-chave
Cryptococcus neoformans, Cryptococcus gattii, IFN-gamma
Referências
  1. Barreto-Bergter E, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00145
  2. Cryptococcosis Consensus Group, 2008, REV SOC BRAS MED TRO, V41, P524
  3. DYKSTRA MA, 1977, INFECT IMMUN, V16, P129, DOI 10.1128/IAI.16.1.129-135.1977
  4. Erwig LP, 2016, NAT REV MICROBIOL, V14, P163, DOI 10.1038/nrmicro.2015.21
  5. Freitas RS, 2017, REV IBEROAM MICOL, V35, P27
  6. Garelnabi M, 2018, MEM I OSWALDO CRUZ, V113, DOI 10.1590/0074-02760180060
  7. Hou XM, 2019, MYCOSES, V62, P937, DOI 10.1111/myc.12966
  8. Huang C, 2002, INFECT IMMUN, V70, P5485, DOI 10.1128/IAI.70.10.5485-5493.2002
  9. Kang X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05199-0
  10. Kassi FK, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007812
  11. Leao CA, 2011, MED MYCOL, V49, P352, DOI 10.3109/13693786.2010.530697
  12. Levitz SM, 2001, P NATL ACAD SCI USA, V98, P10422, DOI 10.1073/pnas.181331398
  13. Levitz SM, 2006, FEMS YEAST RES, V6, P513, DOI 10.1111/j.1567-1364.2006.00071.x
  14. Li YB, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01837
  15. Lipke PN, 1998, J BACTERIOL, V180, P3735, DOI 10.1128/JB.180.15.3735-3740.1998
  16. McFadden D, 2006, TRENDS MICROBIOL, V14, P497, DOI 10.1016/j.tim.2006.09.003
  17. MURPHY JW, 1988, REV INFECT DIS, V10, pS432
  18. Nishikawa MM, 2003, J CLIN MICROBIOL, V41, P73, DOI 10.1128/JCM.41.1.73-77.2003
  19. Okabayashi K, 2005, MYCOPATHOLOGIA, V160, P1, DOI 10.1007/s11046-005-0139-6
  20. Pizani A, 2017, REV SAUDE UNITOLEDO, V1, P90
  21. Zaragoza O, 2009, ADV APPL MICROBIOL, V68, P133, DOI 10.1016/S0065-2164(09)01204-0
  22. Zhu LP, 2010, MED MYCOL, V48, P570, DOI 10.3109/13693780903437876